Enhanced combination cancer therapy using lipid-calcium carbonate/phosphate nanoparticles as a targeted delivery platform.
Melanoma, the most life-threatening skin cancer, requires more effective therapies. A new folic acid (FA) receptor-targeted lipid-coated calcium carbonate/phosphate (LCCP) nanoparticle was synthesized, incorporating two often-used therapeutics, cell death siRNA and α-tocopheryl succinate. The nanoparticles were spherical, with an average size of 40 nm. The nanoparticles exhibited a high gene/drug loading efficiency (60%), with folic acid-enhanced cellular uptake. The nanoparticles with both therapeutics enhanced inhibition of B16F0 melanoma cell growth, showing a moderate synergistic effect. The mechanism of the inhibition is associated with induction of cell apoptosis and cell cycle arrest at G1 phase. Our data indicate that lipid-coated calcium carbonate/phosphate nanoparticles are a potential platform for targeted therapy for melanoma.